On September 9, 2020 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that its chief executive officer, Dr. Gerrit Dispersyn, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference, held virtually this year from September 14 – 16, 2020 (Press release, Phio Pharmaceuticals, SEP 9, 2020, View Source [SID1234564800]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Dispersyn is scheduled to present on Wednesday, September 16th, at 11:30 a.m. ET. Interested parties may access a live webcast of the presentation at View Source

An archived version of the webcast and the slides used in the presentation will be made available on the "Investors – Events and Presentations" section of the Company’s website after the live event.